Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer

Conclusion: ER+PR-HER2- breast cancer consists of clinically and genomically distinct groups that may require different treatment strategies. The non-luminal-like subgroup was associated with reduced benefit from endocrine therapy.

Source: Theranostics - December 6, 2018 Category: Molecular Biology Authors: Xi-Yu Liu, Ding Ma, Xiao-En Xu, Xi Jin, Ke-Da Yu, Yi-Zhou Jiang, Zhi-Ming Shao Tags: Research Paper Source Type: research